Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;26(3):306-310.
doi: 10.1097/GME.0000000000001199.

Amenorrhea after lung cancer treatment

Elizabeth J Cathcart-Rake  1 , Kathryn J Ruddy  1 , Ruchi Gupta  2 , Walter Kremers  2 , Kelly Gast  3 , H Irene Su  4 , Ann H Partridge  5 , Elizabeth A Stewart  6 , Han Liu  7   8 , Yanqi He  7   9 , Ping Yang  7
Affiliations

Amenorrhea after lung cancer treatment

Elizabeth J Cathcart-Rake et al. Menopause. 2019 Mar.

Abstract

Objective: More than 5,000 premenopausal women are diagnosed with lung cancer annually in the United States. Limited data exist regarding the risk of treatment-related amenorrhea, a surrogate for infertility and early menopause, after systemic therapies for lung cancer.

Methods: Premenopausal women diagnosed with lung cancer under age 50 were surveyed at diagnosis and annually thereafter about their menstrual status as a part of the Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program. Types of lung cancer-directed treatments were recorded, and frequencies of self-reported menopause at each survey were calculated.

Results: A cohort of 182 premenopausal women were included in this study, with average age at lung cancer diagnosis 43 years (SD 6). Among the 85 patients who received chemotherapy, 64% self-reported that they had become menopausal within a year of diagnosis. Platinum salts were universally included in these chemotherapy regimens, and the majority of these women also received taxanes within 1 year of diagnosis. Only 15% of the 94 patients who did not receive systemic therapy within 1 year of diagnosis experienced self-reported menopause. Three patients received targeted therapy alone, two of whom remained premenopausal at the final qualifying survey, completed a median of 3 years after diagnosis.

Conclusions: Chemotherapy for lung cancer patients appears to increase risk of early loss of menses in survivors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest for the current study: None. Dr. Cathcart-Rake, Dr. Ruddy, Ms. Gupta, Dr. Gast, Dr. Su, Dr. Partridge, Dr. Liu, Dr. He, and Dr. Yang have nothing to disclose. Dr. Stewart reports personal fees from Gynesonics, Redwood City, CA, personal fees from Bayer, Leverkusen, Germany, personal fees from GlaxoSmithKline, London, United Kingdom, personal fees from Astellas Pharma, Tokyo, Japan, personal fees from Welltwigs, Minneapolis, MN, and personal fees from AbbVie, North Chicago, IL, all outside the submitted work. Dr. Kremers reports funding from AstraZeneca, Cambridge, United Kingdom, Roche, Basel, Switzerland,and Biogen, Cambridge, MA, outside the submitted work.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Health USNIo. National Cancer Institute. SEER Cancer Statistics Review. 1975-2013.
    1. Miller JJ, Williams GF 3rd, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med. 1971;50(4):530–5. - PubMed
    1. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985;55(10):2364–72. - PubMed
    1. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39. - PubMed

Publication types

Substances